Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 8/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15806526 | 0.82 | L3MBTL1 (0.51) | L3MBTL1ZDHHC20ACHEEPHX2 | |
| SCHEMBL16106831 | 0.78 | TSHR (0.44) | L3MBTL1ZDHHC20NPC1ALDH1A1TAAR1 | |
| SCHEMBL13366719 | 0.77 | L3MBTL1 (0.41) | L3MBTL1ZDHHC20NPC1ACHEEPHX2 | |
| SCHEMBL5144907 | 0.77 | ACHE (0.63) | L3MBTL1ZDHHC20ACHE | |
| SCHEMBL16401454 | 0.77 | NPC1 (0.39) | L3MBTL1ZDHHC20NPC1ALDH1A1TAAR1 | |
| SCHEMBL27642692 | 0.76 | L3MBTL1 (0.43) | L3MBTL1ZDHHC20NPC1ACHEEPHX2 | |
| SCHEMBL15549900 | 0.76 | HTT (0.51) | L3MBTL1ZDHHC20ALDH1A1TAAR1ACHE | |
| SCHEMBL1264448 | 0.75 | — | — | |
| SCHEMBL10245233 | 0.75 | — | — | |
| SCHEMBL9196584 | 0.74 | L3MBTL1 (0.64) | L3MBTL1ZDHHC20ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030545-B1 | AMINO ACID DERIVATIVES | MEDIMMUNE LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-9981908-B2 | Amino acid derivatives | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20160176811-A1 | Amino Acid Derivatives | ALLOZYNE, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-3030545-A2 | AMINO ACID DERIVATIVES | Medimmune Limited (GB) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019192-A2 | AMINO ACID DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176811-A1 | Amino Acid Derivatives | BCAT2, BCAT1, DAO | L3MBTL1 490/4885ZDHHC20 2732/4885NPC1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.